Cannabix Technologies Inc (BLOZF)

[High420]

Breathtec Biomedical Inc

I hear rumblings amongst brokers in Vancouver that Breathtec should be trading in Late October..allot of excitement on that one. Breathtec will further breath testing in the field of disease detection with a focus on lung cancer to start.

Also looks like they are considering alzheimers detection..Alzheimers is huge problem in our society and a hand held breath test for early detection would be very disruptive technology in this field.

Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors.
Tisch U1, Schlesinger I, Ionescu R, Nassar M, Axelrod N, Robertman D, Tessler Y, Azar F, Marmur A, Aharon-Peretz J, Haick H.
Author information
Abstract
AIM:
To study the feasibility of a novel method in nanomedicine that is based on breath testing for identifying Alzheimer's disease (AD) and Parkinson's disease (PD), as representative examples of neurodegenerative conditions.
PATIENTS & METHODS:
Alveolar breath was collected from 57 volunteers (AD patients, PD patients and healthy controls) and analyzed using combinations of nanomaterial-based sensors (organically functionalized carbon nanotubes and gold nanoparticles). Discriminant factor analysis was applied to detect statistically significant differences between study groups and classification success was estimated using cross-validation. The pattern identification was supported by chemical analysis of the breath samples using gas chromatography combined with mass spectrometry.
RESULTS:
The combinations of sensors could clearly distinguish AD from healthy states, PD from healthy states, and AD from PD states, with a classification accuracy of 85, 78 and 84%, respectively. Gas chromatography combined with mass spectrometry analysis showed statistically significant differences in the average abundance of several volatile organic compounds in the breath of AD, PD and healthy subjects, thus supporting the breath prints observed with the sensors.
CONCLUSION:
The breath prints that were identified with combinations of nanomaterial-based sensors have future potential as cost-effective, fast and reliable biomarkers for AD and PD.